Compare NBY & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | NEPH |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 31.0M |
| IPO Year | 2007 | 2004 |
| Metric | NBY | NEPH |
|---|---|---|
| Price | $1.95 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 764.8K | 43.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.42 | ★ 1000.00 |
| EPS | ★ 0.76 | 0.11 |
| Revenue | $370,000.00 | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ $2.57 | $26.45 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.43 | $1.78 |
| 52 Week High | $19.95 | $6.42 |
| Indicator | NBY | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 35.77 |
| Support Level | $1.01 | $2.79 |
| Resistance Level | $2.52 | $3.21 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 96.45 | 25.06 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.